KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Pacific Biosciences Of California (PACB) over the last 17 years, with Q3 2025 value amounting to $298.7 million.

  • Pacific Biosciences Of California's Cash & Current Investments fell 3661.13% to $298.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $298.7 million, marking a year-over-year decrease of 3661.13%. This contributed to the annual value of $389.9 million for FY2024, which is 3824.5% down from last year.
  • Pacific Biosciences Of California's Cash & Current Investments amounted to $298.7 million in Q3 2025, which was down 3661.13% from $314.7 million recorded in Q2 2025.
  • In the past 5 years, Pacific Biosciences Of California's Cash & Current Investments registered a high of $1.2 billion during Q1 2021, and its lowest value of $298.7 million during Q3 2025.
  • Its 5-year average for Cash & Current Investments is $731.1 million, with a median of $772.3 million in 2022.
  • In the last 5 years, Pacific Biosciences Of California's Cash & Current Investments surged by 85393.83% in 2021 and then plummeted by 3893.91% in 2025.
  • Pacific Biosciences Of California's Cash & Current Investments (Quarter) stood at $1.0 billion in 2021, then decreased by 26.05% to $772.3 million in 2022, then decreased by 18.24% to $631.4 million in 2023, then plummeted by 38.24% to $389.9 million in 2024, then decreased by 23.41% to $298.7 million in 2025.
  • Its Cash & Current Investments was $298.7 million in Q3 2025, compared to $314.7 million in Q2 2025 and $343.1 million in Q1 2025.